About Candel Therapeutics, Inc.
https://www.candeltx.comCandel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients.
CEO
Paul-Peter Tak FOCIS,
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 56
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Citigroup
Buy
HC Wainwright & Co.
Buy
Canaccord Genuity
Buy
Stephens & Co.
Overweight
B of A Securities
Neutral
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
FMR LLC
Shares:8.23M
Value:$51.13M
ACORN CAPITAL ADVISORS, LLC
Shares:2.58M
Value:$16.03M
BLACKROCK, INC.
Shares:2.38M
Value:$14.78M
Summary
Showing Top 3 of 87
About Candel Therapeutics, Inc.
https://www.candeltx.comCandel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $13.01M ▲ | $-11.27M ▼ | 0% | $-0.21 ▼ | $-10.91M ▼ |
| Q2-2025 | $0 | $10.94M ▲ | $-4.8M ▼ | 0% | $-0.09 ▼ | $-4.32M ▼ |
| Q1-2025 | $0 | $7.88M ▼ | $7.38M ▲ | 0% | $0.23 ▲ | $7.93M ▲ |
| Q4-2024 | $0 | $7.9M ▲ | $-14.07M ▼ | 0% | $-0.4 ▼ | $-13.44M ▼ |
| Q3-2024 | $0 | $3.48M | $-10.65M | 0% | $-0.33 | $-8.51M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $86.96M ▼ | $93.6M ▼ | $13.47M ▼ | $80.12M ▼ |
| Q2-2025 | $100.69M ▲ | $105.97M ▲ | $15.76M ▼ | $90.21M ▲ |
| Q1-2025 | $92.17M ▼ | $95.91M ▼ | $21.23M ▼ | $74.67M ▲ |
| Q4-2024 | $102.65M ▲ | $106.87M ▲ | $40.54M ▲ | $66.33M ▲ |
| Q3-2024 | $16.56M | $21.52M | $36.77M | $-15.26M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-11.27M ▼ | $-10.24M ▼ | $-117K ▼ | $-3.37M ▼ | $-13.72M ▼ | $-10.38M ▼ |
| Q2-2025 | $-4.8M ▼ | $-8.89M ▼ | $-31K ▼ | $17.44M ▲ | $8.52M ▲ | $-8.92M ▼ |
| Q1-2025 | $7.38M ▲ | $-8.62M ▼ | $-3K | $-1.87M ▼ | $-10.49M ▼ | $-8.62M ▼ |
| Q4-2024 | $-14.07M ▼ | $-5.81M ▲ | $-3K ▼ | $91.91M ▲ | $86.1M ▲ | $-5.82M ▲ |
| Q3-2024 | $-10.65M | $-6.57M | $0 | $1.68M | $-4.9M | $-6.57M |
CEO
Paul-Peter Tak FOCIS,
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 56
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Citigroup
Buy
HC Wainwright & Co.
Buy
Canaccord Genuity
Buy
Stephens & Co.
Overweight
B of A Securities
Neutral
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
FMR LLC
Shares:8.23M
Value:$51.13M
ACORN CAPITAL ADVISORS, LLC
Shares:2.58M
Value:$16.03M
BLACKROCK, INC.
Shares:2.38M
Value:$14.78M
Summary
Showing Top 3 of 87